If it works why can't we have it? Sequential anti-TNF therapy in the UK

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2235-2236

  Deighton, Chris ^a  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

COST EFFECTIVENESS ANALYSIS; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDITORIAL; HEALTH ECONOMICS; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78549293295     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq257     Document Type: Editorial

References (8)

1. NICE. Rheumatoid arthritis-drugs for treatment after failure of a TNF inhibitor: final appraisal determination. http://guidance.nice.org.uk/TA/WaveR/61/FAD/FinalAppraisalDetermination/pdf/English (19 July 2010, date last accessed).
2. Lloyd S, Bujkiewicz S, Wailoo AJ, Scott D. The effectiveness of anti-TNF alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta analysis. Rheumatology 2010;49:2213-21.
3. BSR. Prescribing TNF-alpha blockers in adults with rheumatoid arthritis. BSR guideline. 2001, http://www.rheumatology.org.uk/resources/guidelines/guidelines_archive.aspx (19 July 2010, date last accessed).
4. Bansback NJ, Young A, Brennan A. The NICE reappraisal of biologics in 2005: what rheumatologists need to know. Rheumatology 2005;44:3-4.
5. NICE. Rheumatoid arthritis - etanercept and infliximab. 2002, http://guidance.nice.org.uk/TA36 (19 July 2010, date last accessed).
6. Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP. BSR Biologics Register. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology 2008;47:1000-5.
7. NICE. Rheumatoid arthritis - adalimumab, etanercept and infliximab: guidance. 2007, http://guidance.nice.org.uk/TA130/Guidance/pdf/English (19 July 2010, date last accessed).
8. NICE. Rheumatoid arthritis - certolizumab pegol (TA186). 2010, http://www.nice.org.uk/search/guidancesearchresults.jsp?searchType=Guidance&keywords=certolizumab&startYearMonthGF=&endYearMonthGF= (19 July 2010, date last accessed).